Genetic and immunologic therapies for lung cancer

Seminars in Oncology

Volumn 29, Issue 1, 2002, Pages 95-101

  Swisher, Stephen G ^a,b   Roth, Jack A ^a,b   Carbone, David P ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CANCER VACCINE; PROTEIN P53;

ADENOVIRUS; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CLINICAL TRIAL; GENE MUTATION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; LUNG LAVAGE; LUNG NON SMALL CELL CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOSENSITIZATION; REVIEW; TUMOR SUPPRESSOR GENE; VACCINATION;

ADENOVIRIDAE; ANGIOGENESIS INHIBITORS; ANTIBODIES, ANTI-IDIOTYPIC; CANCER VACCINES; CELL TRANSFORMATION, NEOPLASTIC; CLINICAL TRIALS; GENE THERAPY; GENES, P53; HUMANS; IMMUNIZATION; IMMUNOTHERAPY; INTERFERONS; LUNG NEOPLASMS; PROGNOSIS; TRANSDUCTION, GENETIC;

EID: 0036118296     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.31530     Document Type: Article

References (43)

1. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model
2. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus
3. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies
4. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer
5. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer
6. Gene therapy for non-small cell lung cancer: A preliminary report of a phase I trial of adenoviral p53 gene replacement
7. Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type P53 (Ad-p53)
8. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma
9. Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients
10. Bronchioloalveolar carcinoma
11. Bronchioloalveloar carcinoma. A reappraisal after 24 years
12. Bronchiolar carcinoma (alveolar cell) another great imitator: A review of 41 cases
13. Gene therapy for lung cancer: Enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer
14. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer
15. Apoptosis and tumor angiogenesis in cervical cancer after preoperative chemotherapy
16. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: First analysis of a randomized trial in 353 patients
17. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: A randomised multicentre trial
18. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer
19. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation
20. A phase II trial of adenoviral mediated p53 gene transfer (RPR/INGN 201) in conjunction with radiation therapy in patients with localized non-small cell lung cancer (NSCLC)
21. Induction of class I MHC-restricted, peptide-specific cytolytic T lymphocytes by peptide priming in vivo
22. Induction of ovalbumin-specific cytotoxic T cells by in vivo peptide immunization
23. In vivo priming of virus-specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine
24. Adjuvants-A balance between toxicity and adjuvanticity
25. Efficient in vivo induction of CTL by cell-associated covalent H-2Kd-peptide complexes
26. Epitope selection and design of synthetic vaccines: Molecular approaches to enhancing immunogenicity and cross-reactivity of engineered vaccines
27. Genetic immunization is a simple method for eliciting an immune response
28. Heterologous protection against influenza by injection of DNA encoding a viral protein
29. Examination of parameters affecting the elicitation of humoral immune response by particle bombardment-mediated genetic immunization
30. Gene inoculation generates immune responses against human immunodeficiency virus type 1
31. DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations
32. Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes
33. Puncture-mediated gene transfer to the skin
34. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells
35. A comparison of gene transfer methods in human dendritic cells
36. Highly efficient and consistent gene transfer into dendritic cells utilizing a combination of ultraviolet-irradiated adenovirus and poly(L-lysine) conjugates
37. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity
38. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus
39. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells
40. Mutant p53 minigene modified human dendritic cells stimulate tumor-specific cytotoxic T cells
41. Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumor immune responses
42. Effective tumor immunotherapy using bone-marrow derived dendritic cells genetically engineered to express interleukin-12
43. Long survival in 15 patients (pts) with small cell lung cancer (SCLC) immunized with BEC2 plus BCG after initial therapy: An update